Completed PHASE1 INTERVENTIONAL 2-arm NCT02516098

Determine the Bioequivalence of Two Formulations of Hyoscine Butylbromide.

A Single Center, Single-dose, Double-blind, Randomized, Two Period Crossover, Two Stage Design to Determine Bioequivalence of Two Formulations Containing Hyoscine Butylbromide 10mg Sugar Coated Tablets, Under Fasting Conditions

Sponsor: Boehringer Ingelheim

Conditions Healthy

Interventions hyoscine butylbromide

Updated 8 times since 2017 Last updated: Mar 7, 2017 Started: Oct 31, 2015 Primary completion: Dec 31, 2015 Completion: Dec 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Healthy, this trial is completed. The trial is conducted by Boehringer Ingelheim and has accumulated 8 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Dec 2021 — Jul 2024 [monthly]

Completed PHASE1
Jan 2021 — Dec 2021 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 3 earlier versions

May 2017 — Jun 2018 [monthly]

Completed PHASE1
Feb 2017 — May 2017 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Oct 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Boehringer Ingelheim

Data source: Boehringer Ingelheim

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bloemfontein, Canada